Clinical Trials Browser

OTHER × Parkinson Disease 4, Autosomal Dominant Lewy Body × camrelizumab × Clear all

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Phase 2 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body